Inclusion of 26 new therapies on Hungary's subsidy system welcomed by industry
The Hungarian government’s health department has decided to include 26 new medicinal products and indications into the subsidy system, affecting several therapeutic fields, announced Miklós Kásler, Minister of Human Capacities.
The Association of Innovative Pharmaceutical Manufacturers (AIPM) welcomes the government’s decision and trusts that the pace of decisions and inclusions will further increase in the future and the medicinal products will reach the patients as soon as possible, after the procedures have been completed.
Dr Péter Holchacker, director of the AIPM, welcomed the decision that makes advanced therapies available for Hungarian patients for the treatment of additional severe diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze